Regeneron's LAG-3 inhibitor fianlimab fails Phase 3 skin cancer trial

Regeneron announced that its experimental LAG-3 inhibitor fianlimab did not meet its primary endpoint in a late-stage trial for a skin cancer indication.

The Phase 3 study was designed to evaluate the drug’s efficacy and safety compared with standard therapy, but the results showed no statistically significant benefit.

This failure adds to a series of recent setbacks for drugs targeting the LAG-3 pathway, raising concerns about the viability of the class for oncology.